NASDAQ:VTGNVistagen Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vistagen Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.47 +0.00 (+0.65 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$0.45Now: $0.47▼$0.5050-Day Range$0.37MA: $0.42▼$0.5052-Week Range$0.29Now: $0.47▼$1.49Volume637,700 shsAverage Volume448,119 shsMarket Capitalization$23.37 millionP/E RatioN/ADividend YieldN/ABeta0.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingVistagen Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.85, Vistagen Therapeutics has a potential upside of 81.6% from its current price of $0.47.Amount of Analyst CoverageVistagen Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesVistagen Therapeutics has received 255 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVistagen Therapeutics has received 182 “underperform” votes. (Add your “underperform” vote.)Community SentimentVistagen Therapeutics has received 58.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote “Outperform” if you believe VTGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVistagen Therapeutics does not currently pay a dividend.Dividend GrowthVistagen Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.34% of the stock of Vistagen Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 4.83% of the stock of Vistagen Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vistagen Therapeutics are expected to grow in the coming year, from ($0.52) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vistagen Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vistagen Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistagen Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTGN Previous Symbol CUSIPN/A CIK1411685 Webwww.vistagen.com Phone650-577-3600Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book2.75Profitability EPS (Most Recent Fiscal Year)($0.90) Net Income$-24,590,000.00 Net MarginsN/A Return on Equity-1,451.45% Return on Assets-226.50%Miscellaneous Employees9 Outstanding Shares49,938,000Market Cap$23.37 million Next Earnings Date6/23/2020 (Estimated) OptionableNot Optionable NASDAQ:VTGN Rates by TradingView Receive VTGN News and Ratings via Email Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions How has Vistagen Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Vistagen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VTGN stock has decreased by 6.4% and is now trading at $0.4680. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vistagen Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vistagen Therapeutics. When is Vistagen Therapeutics' next earnings date? Vistagen Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, June 23rd 2020. View our earnings forecast for Vistagen Therapeutics. How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics Inc (NASDAQ:VTGN) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.01. View Vistagen Therapeutics' earnings history. What price target have analysts set for VTGN? 3 brokerages have issued 1-year price targets for Vistagen Therapeutics' stock. Their forecasts range from $0.70 to $1.00. On average, they anticipate Vistagen Therapeutics' share price to reach $0.85 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View analysts' price targets for Vistagen Therapeutics. What are Wall Street analysts saying about Vistagen Therapeutics stock? Here are some recent quotes from research analysts about Vistagen Therapeutics stock: 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/25/2020) 2. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019) Has Vistagen Therapeutics been receiving favorable news coverage? Headlines about VTGN stock have been trending somewhat positive on Monday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vistagen Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutVistagen Therapeutics. Are investors shorting Vistagen Therapeutics? Vistagen Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,230,000 shares, a decrease of 8.2% from the April 30th total of 1,340,000 shares. Based on an average daily trading volume, of 377,000 shares, the short-interest ratio is presently 3.3 days. Currently, 3.0% of the company's stock are short sold. View Vistagen Therapeutics' Current Options Chain. Who are some of Vistagen Therapeutics' key competitors? Some companies that are related to Vistagen Therapeutics include Aptorum Group (APM), Catalyst Biosciences (CBIO), Bellerophon Therapeutics (BLPH), TFF Pharmaceuticals (TFFP), CannTrust (CTST), Genprex (GNPX), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN), Proteostasis Therapeutics (PTI), ContraFect (CFRX), Milestone Pharmaceuticals (MIST), Monopar Therapeutics (MNPR), Adamas Pharmaceuticals (ADMS) and SCYNEXIS (SCYX). View all competitors. What other stocks do shareholders of Vistagen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Crispr Therapeutics (CRSP), Matinas BioPharma (MTNB), Lithium Americas (LAC), vTv Therapeutics (VTVT), Sorrento Therapeutics (SRNE) and Yamana Gold (AUY). Who are Vistagen Therapeutics' key executives? Vistagen Therapeutics' management team includes the following people: Mr. Shawn K. Singh, CEO & Director (Age 56)Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)Dr. Mark A. Smith, Chief Medical Officer (Age 64) What is Vistagen Therapeutics' stock symbol? Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN." Who are Vistagen Therapeutics' major shareholders? Vistagen Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Advisor Group Holdings Inc. (0.35%). Company insiders that own Vistagen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe. View institutional ownership trends for Vistagen Therapeutics. Which major investors are buying Vistagen Therapeutics stock? VTGN stock was acquired by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc.. Company insiders that have bought Vistagen Therapeutics stock in the last two years include H Ralph Snodgrass, and Jon S Saxe. View insider buying and selling activity for Vistagen Therapeutics. How do I buy shares of Vistagen Therapeutics? Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vistagen Therapeutics' stock price today? One share of VTGN stock can currently be purchased for approximately $0.47. How big of a company is Vistagen Therapeutics? Vistagen Therapeutics has a market capitalization of $23.37 million. The company earns $-24,590,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe. What is Vistagen Therapeutics' official website? The official website for Vistagen Therapeutics is www.vistagen.com. How can I contact Vistagen Therapeutics? Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
